Research note: Perspectives on the hierarchy of HIV and hepatitis C disease: Consequences for drug treatment program patients

Journal of Drug Issues

Volumn 40, Issue 2, 2010, Pages 517-536

  Munoz Plaza, Corrine ^a   Strauss, Shiela M ^b   Tiburcio, Nelson ^c   Astone Twerell, Janetta M ^c   Des Jarlais, Don C ^b,d,e   Gwadz, Marya ^b,f   Hagan, Holly ^b,g,h   Osborne, Andrew ^b   Rosenblum, Andrew ⁱ  

^a Institute for AIDS Research   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c Samaritan Village Inc ^*

^d Beth Israel Medical Center   (Israel)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f Intervention Studies Methods   (United States)

^g NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ Institute for Treatment and Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956086837     PISSN: 00220426     EISSN: None     Source Type: Journal    
DOI: 10.1177/002204261004000211     Document Type: Article

References (51)

1. Alter, M., Kruszon-Moran, D., Nainan, O., McQuillan, G., Gao, F., Moyer, L., Kaslow, R., & Margolis, H. 1999 The prevalence of hepatitis C virus infection in the United States, 1988-1994. New England Journal of Medicine, 341(8), 556-562.
2. Alter, M., & Moyer, L. 1998 The importance of preventing hepatitis C virus infection among injection drug users in the United States. Journal of Acquired Immune Deficiency Syndrome, 18(Supplement 1), S6-S10.
3. 2: Hepatitis C and drug abuse. HCV Advocate. Retrieved from, http://www.hcvadvocate.org.
4. Borgia, G., Reynaud, L., Gentile, I., & Piazza, M. 2003 HIV and hepatitis C virus: Facts and controversies. Infection, 31(4), 232-240.
5. Centers for Disease Control and Prevention 1998 Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morbidity and Mortality Weekly Report, 47(RR-19), 1-39.
6. Centers for Disease Control and Prevention 2001 HIV Counseling and testing in publicly funded sites. Annals Report 1997 and 1998, 2001.
7. Centers for Disease Control and Prevention 2003 Advancing HIV prevention: New strategies for a changing epidemic-United States. Morbidity and Mortality Weekly Report, 52(15), 329-332.
8. Centers for Disease Control and Prevention 2005 National hepatitis C prevention strategy: Implementation of the national hepatitis C prevention strategy. Retrieved from, http://www.cdc.gov/ncidod/diseases/hepatitis/c/plan/ Implement.htm.
9. Conigliaro, J., Madenwald, T., Bryant, K., Braithwaite, S., Gordon, A., Fultz, S.L., Maisto, S., Samet, J., Kraemer, K., Cook, R., Day, N., Roach, D., Richey, S., & Justice, A. 2004 The Veterans aging cohort study: Observational studies of alcohol use, abuse, and outcomes among Human Immunodeficiency Virus-infected veterans. Alcoholism: Clinical & Experimental Research, 28(2), 313-321.
10. D'Aunno, T., Vaughn, T., & McElroy, P. 1999 An institutional analysis of HIV prevention efforts by the nation's outpatient drug abuse treatment units. Journal of Health & Social Behavior, 40(June), 175-192.
11. Davis, M., Rhodes, T., & Martin, A. 2004 Preventing hepatitis C: 'Common sense', 'the bug' and other perspectives from the risk narratives of people who inject drugs. Social Science & Medicine, 59, 1807-1818.
12. DesJarlais, D. 1990 Stages in the response of the drug abuse treatment system to the AIDS epidemic in New York City. Journal of Drug Issues, 20(2), 335-347.
13. Dhopesh, V.P., Taylor, K.R., Burke, W.M. 2000 Survey of hepatitis B and C in addiction treatment unit. American Journal of Drug and Alcohol Abuse, 26(4), 703-707.
14. Edlin, B. 2002 Prevention and treatment of hepatitis C in injection drug users. Hepatology, 36(5)(Supplement 1), S210-S219.
15. Fultz, S.L., Justice, A.C., Butt, A.A., Rabeneck, L., Weissman, S., & Rodriguez-Barradas, M. 2003 VACS-3 Project team: Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. Clinical Infectious Disease, 56(8), 1039-1046.
16. Garfein, R., Vlahov, D., Galai, N., Doherty, M., & Nelson, K. 1996 Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. American Journal of Public Health, 86(5), 655-661.
17. Hagan, H., & Desjarlais, D. 2000 HIV and HCV infection among injecting drug users. Mount Sinai Journal of Medicine, 67(5&6), 423-428.
18. Hagan, H., Thiede, H., Weiss, N., Hopkins, S., Duchin, J., & Alexander, R. 2001 Sharing of drug preparation equipment as a risk factor for hepatitis C. American Journal of Public Health, 91(1), 42-46.
19. Henry J. Kaiser Family Foundation 2005 HIV/AIDS policy fact sheet: HIV testing in the United States. Publication # 6094-04 June 2005. Retrieved from http://www.kff.org.
20. Hepatitis C Caring Ambassadors Program 2007 Bipartisan hepatitis C legislation reintroduced in both houses of Congress. Retrieved from http://new.marketwire.com/2.0/rel.jsp?id=737507.
21. Liang, T.J., Rehermann, B., Seeff, L.B., & Hoofnagle, J.H. 2000 Pathogenesis, natural history, treatment, and prevention of hepatitis C. Annals of Internal Medicine, 132, 296-305.
22. National Alliance of State and Territorial AIDS Directors: HIV Prevention Bulletin 2001 Integrating viral hepatitis into HIV/AIDS/STD programs Retrieved from http://nastad.org/documents/public/pubprevention/2001828September2001.pdf.
23. National Alliance of State and Territorial AIDS Directors 2002 Viralhepatitis and HIV/AIDS integration: A resource guide for HIV/AIDS programs. Retrieved at: http://nastad.org/documents/public/rograms/ 200203UntegratingViralHepatitisServicesintoHIVandSTDClinic.pdf.
24. National Alliance of State and Territorial AIDS Directors 2008 Support FY2009 Hepatitis Prevention Funding. Retrieved at: http://www.nastad.org/Docs/ Public/Resource/20081014-FY2009%20CDC%20Hep%20Prevention%20Funding.pdf.
25. National Institutes of Health 2002 Management of hepatitis C: 2002. NIH Consensus State-of-the-Science Statements, 19(3), 1-46. Retrieved at http://consensus.nih.gov.
26. Pearlman, B. 2004a Hepatitis C infection: A clinical review. Southern Medical Journal, 97(4), 365-373.
27. Pearlman, B. 2004b Hepatitis C treatment update. American Journal of Medicine, 117(5), 344-352.
28. Prakash, O., Mason, A., Luftig, R.B., & Bautista, A.P. 2002 Hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1) infections in alcoholics. Frontiers in Bioscience, 7, 286-300.
29. Pugatch, D., Levesque, B., Greene, S., Strong, L., Flanigan, T., & Lally, M. 2001 HIV Testing in the setting of inpatient acute substance abuse treatment. American Journal of Drug & Alcohol Abuse, 27(3), 491-499.
30. Rhodes, T., Davis, M., & Judd, A. 2004 Hepatitis C and its risk management among drug injectors in London: Renewing harm reduction in the context of uncertainty. Addiction, 99(5), 621-633.
31. Rotham, J., & Tesoriero, M. 1999 Implementing HIV prevention programs in substance abuse treatment facilities as part of a comprehensive HIV service model eight-year retrospective. Abstract Search Tools National HIV Prevention Conference, Atlanta Ga., Aug 29-Sep 1: (abstract no. 325).
32. © 1991-2006.
33. Seefif, L.B. 1999 Natural history of hepatitis C. American Journal of Medicine, 107(6B), 10S-15S.
34. Sherman, K.E., Rouster, S.D., Chung, R.T., & Rajicic, N. 2002 Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clinical Infectious Diseases, 34, 831-837.
35. Sorenson, J. 1991 Preventing HIV transmission in drug treatment programs: What works? Journal of Addictive Disorders, 10(4), 67-79.
36. Sorensen, J., Masson, C., & Perlman, D. 2002 HIV/Hepatitis prevention in drug abuse treatment programs: Guidance from research. Science Practical Perspectives, July, 4-12.
37. Southgate, E., Weatherall, A.M., Day, C., & Dolan, K. 2005 What's in a virus? Folk understandings of hepatitis C infection and infectiousness among injecting drug users in Kings Cross, Sydney. International Journal of Equity in Health, 4, 5. Published online March 23. Retrieved at: http://www.equityhealthj. eom/content/4/1/5.
38. Staples, C.T., Rimland, D., & Dudas, D. 1999 Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): The effect of coinfection on survival. Clinical Infectious Diseases, 29, 150-154.
39. Strauss, S., Astone, J., DesJarlais, D., & Hagan, H. 2004 A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States. Drug and Alcohol Dependence, 73, 227-236.
40. Strauss, S., Astone, J., DesJarlais, D., & Hagan, H. 2005 Integrating hepatitis C services into existing HIV services: The experiences of a sample of U.S. drug treatment units. AIDS Patient Care & STDs 2005, 19(2), 78-88.
41. Strauss, S., Astone, J., Vassilev, Z., DesJarlais, D., & Hagan, H. 2003 Gaps in the drug-free and methadone treatment program response to hepatitis C. Journal of Substance Abuse Treatment, 24, 291-297.
42. Strauss, S., DesJarlais, D., Astone, J., & Vassilev, Z. 2003 On-site HIV testing in residential drug treatment units: Results of a nationwide survey. Public Health Report, 118, 37-43.
43. Strauss, S., Falkin, G., Vassilev, Z., DesJarlais, D., & Astone, J. 2002 A nationwide survey of hepatitis C services provided by drug treatment programs. Journal of Substance Abuse Treatment, 22, 55-62.
44. Sulkowski, M.S., & Thomas, D.L. 2003 Hepatitis C in the HIV infected person. Annals of Internal Medicine, 138(3), 197-207.
45. Sullivan, L.E., & Fiellin, D.A. 2004 Hepatitis C and HIV infections: Implications for clinical care in injection drug users. American Journal of Addiction, 13(1), 1-20.
46. Teo, M., & Hayes, R 2004 Management of hepatitis C. British Medical Journal, 70, 51-69.
47. The Body: The Complete HIV/AIDS Resource 2007 Retrieved at: http://www.thebody.com/content/treat/art469.html.
48. Thomas, D.L. 2002 Hepatitis C and human immunodeficiency virus infection. Hepatology, 36(5 Suppl 1), S201-S209.
49. U.S. Department of Health and Human Services: Health Resources and Services Administration, HIV/AIDS Bureau, Ryan White CARE Act 2007 Retrieved at: http://hab.hrsa.gov.
50. World Health Organization 2000 Hepatitis C: Global prevalence. Weekly Epidemiology Record, 3, 18-19.
51. Zeuzem, S. 2005 Treatment of hepatitis C virus infection. Schweiz Rundsch Med Prax, 94(18), 721-726.